Study S002313

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of SYH2069 Injection in Participants With Type 2 Diabetes Mellitus With Inadquate Glycemic Control After Diet and Exercise Alone or Metformin Monotherapy

ClinicalTrials.gov record

Registration

Registration: NCT07796477
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 240
Start: 2026-11-06
Primary completion: 2027-09-28
Lead sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: DRUG:SYH2069 Injection (group 1); DRUG:SYH2069 Injection (group 2); DRUG:SYH2069 Injection (group 3); DRUG:SYH2069 Injection (group 4); DRUG:SYH2069 Injection placebo; DRUG:Tirzepatide Injection 15mg
Results posted: FALSE

Registered primary outcomes

Change from baseline in Hemoglobin A1c (HbA1c) [Baseline，Week 28]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.